Compare Estee Lauder Companies Inc (EL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs IDEXX Laboratories, Inc. — how do they compare? Estee Lauder Companies Inc trades at $88.21 (market cap $31.76B), while IDEXX Laboratories, Inc. trades at $572.36 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| EL | IDXX | |
|---|---|---|
Market Cap | $31.76B | $46.22B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $766.68 |
52-Week Low | $67.23 | $526.44 |
Enterprise Value | $37.93B | $47.12B |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EL trades at $88.56, up 1.57% today, with a bullish technical trend and strong recent earnings beats. The stock shows robust gross margins of 74.71% but faces profitability challenges with a negative net income margin. Analyst consensus is mixed with a $91.67 price target, while recent news highlights new product launches and institutional accumulation.
Outlook remains cautiously optimistic given earnings momentum and brand strength, but high valuation multiples and inconsistent cash flow pose risks. Investors should weigh growth potential against margin pressures and macroeconomic sensitivity in the beauty sector.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
